Alethia Young
Stock Analyst at Cantor Fitzgerald
(3.68)
# 716
Out of 4,784 analysts
141
Total ratings
54.46%
Success rate
30.64%
Average return
Main Sectors:
Stocks Rated by Alethia Young
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCUS Arcus Biosciences | Reiterates: Overweight | n/a | $8.17 | - | 5 | Jul 5, 2024 | |
| ARWR Arrowhead Pharmaceuticals | Reiterates: Overweight | n/a | $13.82 | - | 5 | Jun 20, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $800 → $850 | $637.36 | +33.36% | 9 | Oct 16, 2023 | |
| ALXO ALX Oncology Holdings | Reiterates: Overweight | $18 | $0.66 | +2,647.67% | 6 | Sep 12, 2023 | |
| CRIS Curis | Reiterates: Overweight | $60 | $2.32 | +2,486.21% | 3 | Sep 7, 2023 | |
| ELDN Eledon Pharmaceuticals | Reiterates: Overweight | $9 | $3.35 | +168.66% | 2 | Aug 22, 2023 | |
| VSTM Verastem | Reiterates: Overweight | $34 | $6.19 | +449.27% | 2 | Jul 6, 2023 | |
| BIIB Biogen | Maintains: Neutral | $427 → $327 | $138.37 | +136.32% | 7 | Oct 15, 2021 | |
| ADVM Adverum Biotechnologies | Downgrades: Neutral | $230 → $30 | $4.61 | +550.76% | 4 | Jul 23, 2021 | |
| RAPT RAPT Therapeutics | Maintains: Overweight | $51 → $71 | $1.22 | +5,719.67% | 2 | Jun 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $285 → $281 | $492.69 | -42.97% | 5 | Jun 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $8 | $1.91 | +318.85% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $86 → $98 | $0.85 | +11,438.91% | 3 | Feb 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $280 → $295 | $306.95 | -3.89% | 9 | Feb 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $84 → $86 | $111.79 | -23.07% | 3 | Oct 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $48 | $39.86 | +20.42% | 4 | Oct 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $8.97 | +234.45% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $72 | $30.28 | +137.78% | 8 | Jul 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $5 | $1.14 | +338.60% | 5 | Jun 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $83 → $100 | $60.60 | +65.02% | 6 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $185 → $201 | $154.68 | +29.95% | 6 | Apr 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $86 → $85 | $54.24 | +56.71% | 5 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $32 | $8.29 | +286.01% | 1 | Mar 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $211 → $217 | $70.41 | +208.19% | 12 | Feb 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $75 → $48 | $18.95 | +153.30% | 4 | Oct 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $12.11 | - | 3 | Mar 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $151 → $154 | $268.46 | -42.64% | 5 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $113 → $116 | $71.44 | +62.37% | 2 | Mar 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $147 → $106 | $3.14 | +3,275.80% | 8 | Jan 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $28 | $8.07 | +246.96% | 1 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $85 → $82 | $205.13 | -60.03% | 2 | Sep 27, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | n/a | $306.97 | - | 1 | Mar 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.98 | - | 1 | Oct 18, 2016 |
Arcus Biosciences
Jul 5, 2024
Reiterates: Overweight
Price Target: n/a
Current: $8.17
Upside: -
Arrowhead Pharmaceuticals
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $13.82
Upside: -
Regeneron Pharmaceuticals
Oct 16, 2023
Maintains: Neutral
Price Target: $800 → $850
Current: $637.36
Upside: +33.36%
ALX Oncology Holdings
Sep 12, 2023
Reiterates: Overweight
Price Target: $18
Current: $0.66
Upside: +2,647.67%
Curis
Sep 7, 2023
Reiterates: Overweight
Price Target: $60
Current: $2.32
Upside: +2,486.21%
Eledon Pharmaceuticals
Aug 22, 2023
Reiterates: Overweight
Price Target: $9
Current: $3.35
Upside: +168.66%
Verastem
Jul 6, 2023
Reiterates: Overweight
Price Target: $34
Current: $6.19
Upside: +449.27%
Biogen
Oct 15, 2021
Maintains: Neutral
Price Target: $427 → $327
Current: $138.37
Upside: +136.32%
Adverum Biotechnologies
Jul 23, 2021
Downgrades: Neutral
Price Target: $230 → $30
Current: $4.61
Upside: +550.76%
RAPT Therapeutics
Jun 14, 2021
Maintains: Overweight
Price Target: $51 → $71
Current: $1.22
Upside: +5,719.67%
Jun 11, 2021
Maintains: Overweight
Price Target: $285 → $281
Current: $492.69
Upside: -42.97%
Mar 8, 2021
Initiates: Overweight
Price Target: $8
Current: $1.91
Upside: +318.85%
Feb 25, 2021
Maintains: Overweight
Price Target: $86 → $98
Current: $0.85
Upside: +11,438.91%
Feb 3, 2021
Maintains: Overweight
Price Target: $280 → $295
Current: $306.95
Upside: -3.89%
Oct 29, 2020
Reiterates: Overweight
Price Target: $84 → $86
Current: $111.79
Upside: -23.07%
Oct 28, 2020
Maintains: Overweight
Price Target: $30 → $48
Current: $39.86
Upside: +20.42%
Oct 12, 2020
Initiates: Overweight
Price Target: $30
Current: $8.97
Upside: +234.45%
Jul 31, 2020
Maintains: Overweight
Price Target: $70 → $72
Current: $30.28
Upside: +137.78%
Jun 2, 2020
Assumes: Overweight
Price Target: $5
Current: $1.14
Upside: +338.60%
May 19, 2020
Maintains: Neutral
Price Target: $83 → $100
Current: $60.60
Upside: +65.02%
Apr 20, 2020
Reiterates: Overweight
Price Target: $185 → $201
Current: $154.68
Upside: +29.95%
Apr 8, 2020
Reiterates: Overweight
Price Target: $86 → $85
Current: $54.24
Upside: +56.71%
Mar 6, 2020
Maintains: Overweight
Price Target: $30 → $32
Current: $8.29
Upside: +286.01%
Feb 27, 2020
Reiterates: Overweight
Price Target: $211 → $217
Current: $70.41
Upside: +208.19%
Oct 3, 2019
Maintains: Neutral
Price Target: $75 → $48
Current: $18.95
Upside: +153.30%
Mar 22, 2018
Downgrades: Underperform
Price Target: n/a
Current: $12.11
Upside: -
Mar 13, 2018
Maintains: Outperform
Price Target: $151 → $154
Current: $268.46
Upside: -42.64%
Mar 2, 2018
Maintains: Outperform
Price Target: $113 → $116
Current: $71.44
Upside: +62.37%
Jan 24, 2018
Maintains: Outperform
Price Target: $147 → $106
Current: $3.14
Upside: +3,275.80%
Nov 3, 2017
Maintains: Outperform
Price Target: $24 → $28
Current: $8.07
Upside: +246.96%
Sep 27, 2017
Maintains: Neutral
Price Target: $85 → $82
Current: $205.13
Upside: -60.03%
Mar 16, 2017
Initiates: Underperform
Price Target: n/a
Current: $306.97
Upside: -
Oct 18, 2016
Initiates: Outperform
Price Target: n/a
Current: $1.98
Upside: -